Oral substitution treatments for opioid dependence

The Lancet

Volumn 371, Issue 9631, 2008, Pages 2150-2151

  Hall, Wayne D ^a   Mattick, Richard P ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHADONE; NALTREXONE; PLACEBO;

ARTICLE; CLINICAL TRIAL; DRUG DEPENDENCE TREATMENT; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SAFETY; HUMAN; OPIATE ADDICTION; PRIORITY JOURNAL;

EID: 45849140199     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60930-7     Document Type: Note

References (13)

1. Degenhardt L., Hall W., Warner-Smith M., and Lynskey M. Illicit drug use. In: Ezzati M., Lopez A., Rodgers A., and Murray C. (Eds). Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors (2004), World Health Organization, Geneva 1109-1176
2. Ezzati M., Lopez A., Rodgers A., Vander Hoorn S., Murray C., and the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 360 (2002) 1347-1360
3. Van den Brink W., and Haasen C. Evidenced-based treatment of opioid-dependent patients. Can J Psychiatry 51 (2006) 635-646
4. Mattick R., and Hall W. Are detoxification programmes effective?. Lancet 347 (1996) 97-100
5. Minozzi S., Amato L., Vecchi S., Davoli M., Kirchmayer U., and Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2 (2006) CD001333.
6. Digiusto E., Shakeshaft A., Ritter A., O'Brien S., and Mattick R. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 99 (2004) 450-460
7. Hall W., Doran C., Degenhardt L., and Shepard D. Illicit opioid dependence. In: Jamison D., Evans D., and Alleyne G. (Eds). Disease control priorities for developing countries. 2nd edn. (2006), Oxford University Press, New York 907-931
8. Bird S., and Hutchinson S. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996-99. Addiction 98 (2003) 185-190
9. Strang J., McCambridge J., Best D., et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 326 (2003) 959-960
10. Schottenfeld R., Chawarski M., and Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008) 2192-2200
11. Mattick R., Kimber J., Breen C., and Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 3 (2004) CD002207.
12. Amato L., Davoli M., Perucci C., Ferri M., Faggiano F., and Mattick R. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 28 (2005) 321-329
13. Mattick R., Breen C., Kimber J., and Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2 (2003) CD002209.